DGAP-News: Press Release 4SC AG: 4SC receives milestone payment from research collaboration with SKK
(firmenpresse) - DGAP-News: 4SC AG / Key word(s): Alliance/Miscellaneous
Press Release 4SC AG: 4SC receives milestone payment from research
collaboration with SKK
30.04.2012 / 07:30
---------------------------------------------------------------------
Press Release
4SC receives milestone payment from research collaboration with SKK
Planegg-Martinsried, Germany, 30 April 2012 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for autoimmune diseases and cancer, today announced that it
has received a milestone payment from the Japanese pharmaceutical company
Sanwa Kagaku Kenkyusho Co. Ltd., Nagoya (SKK) under a previously-concluded
research collaboration.
The milestone payment will go to 4SC Discovery GmbH, a wholly-owned
subsidiary of 4SC AG specialising in the early-stage biopharmaceutical
research and discovery of new drug substances.
Under the research collaboration, 4SC had contributed its know-how in the
field of medicinal chemistry together with its expertise in computerised
(in silico) screening and modelling for the rapid discovery, selection and
optimisation of new drug substances (hits and leads) to investigate new
classes of substances for the potential therapy of metabolic diseases. In
its pharmaceutical research and development work, SKK has now achieved
decisive progress with an optimised chemical compound resulting from this
collaboration, which triggered the contractually-agreed milestone payment.
Dr. Daniel Vitt, Chief Scientific Officer of 4SC AG and Managing Director
of 4SC Discovery GmbH commented: 'We are very pleased to have received this
milestone payment. This success further stresses our long-standing research
expertise and the capabilities of our core technology for the discovery and
optimisation of new pharmaceutical compounds, a technology that we have
been marketing more actively since early 2012 with the newly-launched 4SC
Discovery. Our special thanks are due to our partner SKK for the fruitful
and pleasant collaboration. We intend to use this and, in the future,
similar ventures to further strengthen the business of both 4SC Discovery
and the entire 4SC Group.'
End of press release
About 4SC
The Group (4SC) managed by 4SC AG (ISIN DE0005753818) discovers and
develops targeted, small-molecule drugs for treating diseases with a high
unmet medical need in various autoimmune and cancer indications. These
drugs are intended to provide innovative treatment options that are more
tolerable and efficacious than existing therapies, and provide a better
quality of life. 4SC AG, as the Group parent company, is concentrating on
the clinical development of the drugs and their commercialisation together
with pharmaceutical partners. 4SC Discovery GmbH, the fully-owned
subsidiary of 4SC AG, is focused on the research and discovery of new
therapeutic compounds - a measure also intended to further enhance the
clinical development pipeline of 4SC AG - as well as their early-stage
commercialisation. In addition, 4SC Discovery enters into service and
collaboration agreements with pharmaceutical and biotech partners in the
field of drug discovery. 4SC was established in 1997 and had 96 employees
at the end of 2011. 4SC AG has been listed on the Prime Standard at the
Frankfurt Stock Exchange since December 2005.
About SKK
Sanwa Kagaku Kenkyusho Co., Ltd. (SKK) is a fully-integrated pharmaceutical
company headquartered in Nagoya, Japan. Their business is concentrated in
research and development, manufacture, and sales of ethical
pharmaceuticals, diagnostics, medical foods, health care products and
contract manufacturing of pharmaceuticals. SKK's targeted therapeutic areas
are metabolic disorders, renal diseases and ophthalmic diseases.
Further information is available at: http://www.skk-net.com/en/
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information please visit www.4sc.com and www.4sc-discovery.com or
contact:
4SC AG
Jochen Orlowski, Corporate Communications&Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49 (0) 89 70 07 63 66
MC Services
Raimund Gabriel
raimund.gabriel(at)mc-services.eu , Tel.: +49 (0) 89 21 02 28 30
Mareike Mohr
mareike.mohr(at)mc-services.eu, Tel.: +49 (0) 89 21 02 28 40
The Trout Group (USA)
Chad Rubin
Crubin(at)troutgroup.com, Tel.: +1 646 378 2947
End of Corporate News
---------------------------------------------------------------------
30.04.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
167190 30.04.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.04.2012 - 07:30 Uhr
Sprache: Deutsch
News-ID 140339
Anzahl Zeichen: 7271
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 419 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Press Release 4SC AG: 4SC receives milestone payment from research collaboration with SKK"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
